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250 word structured summary 
Background: Healthcare-associated infection (HAI) affects millions of patients worldwide. 
HAI is associated with increased healthcare costs, owing primarily to increased hospital 
length of stay (LOS) but calculating these costs is complicated due to time-dependent bias. 
Accurate estimation of excess LOS due to HAI is essential to ensure we invest in cost-
effective infection prevention and control (IPC) measures. 
Aim: To identify and review the main statistical methods that have been employed to 
estimate differential LOS between patients with, and without, HAI; to highlight and discuss 
potential biases of all statistical approaches. 
Methods: A systematic review from 1997 to April 2017 was conducted in PUBMED, CINAHL, 
PROQUEST and ECONLIT databases. Studies were quality assessed using an adapted 
Newcastle-Ottawa Scale (NOS). Methods were categorised into time-fixed or time-varying 
with the former exhibiting time-dependent bias. We use two examples of meta-analysis to 
illustrate how estimates of excess LOS differ between different studies. 
Findings: Ninety-one studies with estimates on excess LOS were identified. The majority of 
articles employed time-fixed methods (76%). Studies using time-varying methods are of 
higher quality according to NOS. Studies using time-fixed methods overestimate additional 
LOS attributable to HAI. Undertaking meta-analysis is challenging due to a variety of study 
designs and reporting styles. Study differences are further magnified by heterogeneous 
populations, case definitions, causative organisms and susceptibilities. 
Conclusions: Methodologies have evolved over the last 20 years but there is still a 
significant body of evidence reliant upon time-fixed methods. Robust estimates are required 
to inform investment in cost-effective IPC interventions. 
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1 Introduction 
 
Healthcare-Associated Infection (HAI) is a major issue for health providers, patients and 
public authorities worldwide.[1] The total annual number of patients with an HAI in 
European acute care hospitals was recently estimated at 3.2 million.[2] HAI has been 
associated with a significant impact on morbidity and mortality and can create substantial 
excess costs for health provision by prolonging hospital stay.[3] Accurate measurement of 
HAI costs is essential for developing cost-effective Infection Prevention and Control (IPC) 
measures. A major component of these costs can be captured by measuring the additional 
Length of Stay (LOS) due to HAI.[4, 5] This is complicated due to the fact that infection 
increases the duration of hospital stay but, at the same time, the risk of infection increases 
with duration of stay.[6] In addition, patients with longer LOS tend to be more at risk of HAI 
due to various characteristics and co-morbidities. HAI should be treated as a time-
dependent event that is not present on admission otherwise estimates of excess LOS are 
biased.[3, 6-8]  
There have been a number of literature reviews focusing on LOS and economic burden 
due to HAI. Shulgen et al reviewed two studies to illustrate the concept of time-dependent 
bias. [9] Mitchel et al published an integrative review on statistical methods used to 
examine LOS due to C. difficile infections with a focus on time-dependent bias.[10] Gandra 
et al examined antimicrobial resistance and discuss time-dependent bias when estimating 
cost.[11] De Angelis et al made the case for focusing on LOS when estimating HAI economic 
burden, reviewed methods to estimate LOS and criticised time-fixed methods that treat HAI 
as artificially present on admission.[12] Seven studies were reviewed by Nelson et al and 
highlighted the issue of time-dependent bias by comparing methods that treat HAI exposure 
as time fixed versus a time varied event.[13] Fukuda et al reviewed analytical methodologies 
for estimating additional healthcare cost of HAI.[14] They raise the importance of adjusting 
for LOS and employing good statistical methods. Stone et al reviewed economic analyses of 
HAI and recommended use of guidelines and appropriate methods.[15] Variability in 
methods estimating the economic cost of HAI arises for a number of reasons; these include 
differences in case definitions, patient populations and whether the study design is 
prospective or retrospective.[11] It has been suggested that meaningful comparisons can 
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only be made if uniform definitions of rates are adopted along with standardised methods 
of data collection.[16] More recently Perencevich et al stated that stringent research 
standards are required to make the case for investing in IPC interventions with a blueprint 
on how to achieve this.[17]  It is uncertain whether these recommendations have been fully 
adopted. In the UK the main findings from the seminal Plowman study are still referenced 
but we should recognise the methodological limitations.[18] 
In this paper we present a systematic review with two aims. First, to identify and review 
which statistical methods have been used to estimate differential LOS between patients 
with, and without, HAI and second, to assess the quality of studies and illustrate differences 
between the statistical methodologies with a particular focus on time-dependent bias. This 
is a unique review of studies with excess LOS estimates across all HAI types during the last 
twenty years. The review examines the current standard of research, identifies methods to 
estimate excess LOS due to HAI and proposes recommendations for the future.  
2 Methods 
 
This systematic review is PROSPERO registered (registration number: CRD42016050094); it 
adheres to recommendations in the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement and guidance from the Campbell and Cochrane 
Economics Methods Group on incorporating economic evidence into systematic 
reviews.[19, 20] 
The literature was reviewed from 1st January 1997 to 30th April 2017 to identify 
relevant English language articles published in PUBMED, CINAHL, PROQUEST and ECONLIT 
databases. The search strategy combined the general “Cross Infection” MeSH heading with 
various nosocomial infection terms, major HAI types and economic or LOS terms (Appendix 
1). HAI types were categorised based on European Centre for Disease Prevention and 
Control (ECDC) definitions.[21] Given the changing nature of acute hospital care, a 20 year 
period was chosen in order to include as many studies as possible while retaining studies 
that are still relevant today.  
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2.1 Selection criteria 
 
All studies were assessed for eligibility by applying the PICOS (population, intervention, 
comparison, outcomes and setting) question format.[19] Publications identified in the 
search were combined and duplicates removed. A two-step review process was undertaken. 
The first step consisted of a title-abstract review and the second step of a full article review. 
Two authors (SM, SS) independently examined the titles and abstracts identified by the 
search strategy to select articles. Studies that were identified by only one author (SM) were 
discussed by a third (AM) to determine if they met the eligibility criteria for inclusion in the 
Review. Disagreements were resolved by discussion between the three authors (SM, SS, 
AM). 
The PICOS inclusion and exclusion criteria applied were: 
 Population We included studies with adult inpatients who had a documented HAI in 
a health facility. Studies were excluded if they did not clearly distinguish between 
colonisation, community onset infections and HAI. Studies without a non-HAI 
comparison group were excluded. 
 Intervention We included observational studies; interventions were not considered 
when including or excluding papers.  
 Control/design We included case controlled and cohort studies. Case controlled 
studies allocated patients according to their HAI status. Commentaries and reviews 
were excluded.  
 Outcome Studies were included if they attempted to measure and report LOS using 
any statistical method. Studies which did not report LOS data were excluded. Studies 
were required to report total LOS from admission to discharge. Studies measuring 
partial LOS were excluded (e.g. only reporting duration of stay in a single specialty). 
 Setting We included studies in any health care setting with populations typical of 
acute care inpatient wards and critical care units. We excluded studies with selected 
populations; inpatients and outpatients or patients in residential care.  
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2.2 Data extraction  
 
An initial scoping review was undertaken for the selected papers with a set of classifications 
developed for analysis types.  Six statistical methods were identified and divided into two 
high level groups. The first group treats HAI as present on admission or as time fixed and the 
second treats HAI as a time-dependent event or as time varied. Matching studies that did 
not match on the timing of infection will be referred to as Matching (Simple) and matching 
studies that matched on the timing to infection are referred to as Matching (Time).  Group 
comparison, Matching (Simple) and regression techniques that do not take the timing of 
events into account are referred to as time-fixed. Matching (Time), Survival Analysis and 
Multistate Modelling control for the time-dependence of HAI are referred to as time-
varying.[22]Survival analysis can also be a time-fixed approach but the identified survival 
analysis studies treated HAI as time-varying and therefore survival analysis was placed in the 
second group. A more detailed description of these methodologies is described within 
Supplementary material 5. 
Extraction of data was performed by one investigator (SM). Two authors (SS, AM) checked 
10% of this work for consistency. Any disagreements were resolved by consensus of these 
three authors. Data extraction was recorded on a Microsoft Excel template with the 
following columns: authors, year of publication, HAI type, organism (if reported), study 
design, statistical method, excess LOS due to HAI, confidence interval, sample size, year of 
data collection, journal title, country, country income classification, hospital setting, 
information on antibiotics (Yes/No) and discussion of time-dependent bias (Yes/No). 
Countries were grouped into high and middle income based on the World Bank country 
income classification.[23]   
HAI type was defined based on the way papers reported their results. When papers 
reported outcomes for different HAI types we extracted these separately. We defined an 
HAI group where papers reported results for multiple types of HAI in a single measure. For 
example a paper that reported the cost of HAI overall without distinguishing between the 
different subtypes would go into this group. Excess LOS due to HAI was not always available 
as a separate estimate since some studies reported LOS outcomes separately for an HAI and 
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a non-HAI group. There were notable differences in the way studies reported their 
estimates and therefore we only report LOS outcomes in the studies selected for meta-
analysis. Where studies reported results for more than one HAI we extracted estimates 
separately for each HAI. Most studies reported standard deviations or confidence intervals 
but only standard errors or p-values were provided in some papers. Studies that used 
regression methods or multistate modelling reported estimates of impact on LOS in excess 
days with a 95% confidence interval. When more than one method was used we extracted 
the main method and associated estimate. For example, when group comparison estimates 
were present along with estimates from another method we only extracted the latter. For 
bloodstream infection studies, we extracted multiple estimates for a single HAI (see section 
2.4). We followed recommendations by the Cochrane collaboration for calculating 
confidence intervals in studies where this information was not provided.[19] 
2.3 Quality Assessment 
 
Quality assessment was carried out using Newcastle Ottawa Scale (NOS).[24, 25] NOS is a 
quality assessment tool for use on nonrandomized studies included in systematic reviews, 
specifically cohort and case-control studies. A star rating system is used to indicate the 
quality of a study, with a maximum assessment of nine stars.[25] Each criterion receives 
zero, one or two stars with more stars indicating higher compliance. As suggested by the 
Cochrane collaboration we modified NOS to represent issues specific to studies estimating 
excess LOS due to HAI.[19] Our version of NOS assesses study design, HAI case definitions 
and application of appropriate statistical methods. The main changes from the original NOS 
are defining the exposure as HAI, the outcome as LOS, wording to reflect application of case 
definitions and allocation of one star to studies employing a time-varying statistical method. 
The rest of the criteria are the same as the original NOS. The only items where it was 
possible to receive two stars was for applying internationally recognised case definitions to 
records, e.g. CDC and ECDC, and for employing appropriate sampling strategies either as 
cohort or case control studies. The maximum number of stars possible was eight. One 
author (SM) assessed all included articles and two authors (SS, AM) checked 10% of this 
work for consistency. Any disagreements were resolved by consensus of the three authors. 
Supplementary material 3 details the version of NOS applied to the articles included in this 
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review. Quality assessment was done for each LOS estimate separately. Error! Reference 
source not found. shows the total number of stars awarded to each LOS estimate and 
Supplementary material 4 provides a detailed breakdown of quality assessment. 
2.4 Statistical Analysis 
Stata statistical software was used to conduct all statistical analyses.[26] A Wilcoxon-Mann-
Whitney (WMW) test on the equality of means was performed to test if statistical 
methodology has an impact on article quality. When applying this test we excluded the NOS 
item on statistical methods since only time-varying methods could be allocated a star there. 
Meta-analysis: As discussed earlier the study designs showed a large amount of 
heterogeneity. In order to minimise differences in populations and potential impact on 
excess LOS, we focused on high income countries and chose two commonly occurring HAI 
types. The first meta-analysis focuses on estimates of impact of Bloodstream Infection (BSI) 
(17 studies) on LOS and the second on Gastrointestinal Infection (GI) (19 studies) caused by 
Clostridium difficile infection (CDI). Bloodstream infections are known to increase LOS and 
cause significant impact on patient morbidity and mortality.[27] HAI CDI was selected as it is 
a single causative organism for gastrointestinal diarrheal disease and would provide an 
important difference on statistical methodology in the CDI meta-analysis. CDI HAI obviates 
the variation due to different causative organisms present in the BSI infections. The 
heterogeneity among studies was estimated by the I2 statistic.[28] We used a random-
effects estimator to calculate pooled estimates of excess LOS due to HAI.[28, 29] The Stata 
metan routine was used to display meta-analysis results graphically in forest plots.[26, 30] 
For meta-analysis we extracted excess LOS estimates in days and calculated standard errors 
as recommended by the Cochrane collaboration. In cases where LOS of cases and controls 
was available separately, we extracted LOS for both of these groups and calculated the 
difference. Where different estimates for susceptible and resistant organisms were reported 
we extracted excess LOS for both. In the BSI group we extracted 31 excess LOS estimates 
from 17 studies where more than one method was used or information on more than one 
organism or different antibiotic susceptibilities were reported. In the CDI group we 
extracted one estimate from each study, 19 estimates in total.     
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3 Results 
The main characteristics of the studies included and the statistical methods identified are 
shown on Error! Reference source not found.. There were: 23 studies[27, 31-52] with an 
estimate of impact of BSI on LOS; 22 studies[51, 53-73] with estimates from the impact of 
GI; 27 studies[38, 43, 44, 48, 51, 74-95] with estimates from Surgical Site Infection (SSI); 26 
studies[4, 22, 44, 48, 51, 80, 81, 86, 96-113] with an average estimate from all types of HAI; 
ten studies[36, 38, 43, 44, 46, 48, 51, 81, 114, 115] with estimates from Urinary Tract 
Infection (UTI); eight studies[36, 38, 43, 48, 114, 116-118] with estimates from Pneumonia; 
four studies[44, 51, 81, 100] with estimates from Lower Respiratory Tract Infection (other 
than Pneumonia); and one study[119] of Bone and Joint Infection. In total we extracted 121 
LOS estimates shown in supplementary material 1 from 92 studies. 
See supplementary material 1 for a summary of the characteristics of the published studies. 
Some authors reported more than one infection type and therefore appear in multiple HAI 
groups. Studies employed data collected in multiple years and there was some overlap 
between selected studies. Table I shows the types of infections, statistical methodologies 
used to estimate excess LOS, country study design and year. As described earlier statistical 
methods were categorised in time-fixed and time-varying according to their treatment of 
the timing of HAI.[13]  
There were 81 studies[4, 22, 27, 32-40, 42-44, 47-72, 74-78, 80-96, 98, 100-103, 105-108, 
110-117, 119] from high income countries, of which 40% took place in the US and 22% in 
the UK, Spain and Australia, and eleven studies[31, 41, 45, 46, 73, 79, 97, 99, 104, 109, 118] 
from middle income countries. The majority (80%) of studies were cohort studies and we 
included 18 studies with a case-control design. The majority of the studies collected data 
during the period 2005 to 2012. The most frequent statistical method employed in the 
included articles is simple matching (31 studies, 34%) followed by regression (24 studies, 
26%), group comparison (14 studies, 15%), matching on time (12 studies, 13%), multistate 
modelling (9 studies, 10% and survival analysis (2 studies, 2%). There were 12 studies that 
investigated more than one HAI types and from these we extracted more than one 
estimates, one for each HAI.[36, 38, 43, 44, 46, 48, 51, 80, 81, 86, 100, 114]  
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Figure 2 shows trends in statistical techniques in published articles over the last two 
decades. Time-fixed methods are the largest proportion (73%) of statistical techniques used 
to estimate excess LOS. In our sample studies using time-varying methods appear in 2006 
and 59% of these used matching on time to infection techniques.[86]  Group comparison 
studies are still being published and 12% of articles have used this method since 2006. 
Overall, only 32% of studies published since 2006 have used time-varying methods.  
Figure 3 shows that time-fixed methods have been used in the majority of articles in every 
year except 2008. Time-fixed methods continue to be the most common methodology used 
in HAI studies. This review included two survival analysis studies and nine multistate 
modelling studies (Table I). Nine articles from middle income countries used either a group 
comparison[73, 97, 99, 109, 118] approach or a simple matching method.[41, 45, 79, 104] 
One article from the middle income country group used a regression model[46] and one 
article used matching on the time to infection.[31]  
Quality assessment NOS scores of seven or eight were considered as high-quality, five or six 
as moderate quality and low quality for less than five. Approximately 57% of estimates were 
of high quality receiving seven or eight stars. Articles using time-varying methods are of 
higher quality than articles with time-fixed methods. Figure 4 summarises the results of the 
quality assessment by type of statistical method. NOS allocates seven stars out of eight to 
study design. Articles using time-varying methods scored significantly (z=3.172, P<.002) 
higher in the quality assessment. When performing the WMW test we excluded the NOS 
item that is related to methods since only time-varying methodologies could be awarded a 
star and we wanted to compare quality as captured by the NOS items on study design. One 
reason that time-fixed methods were assessed to be of lower quality is that only 55% of 
these applied case definitions to identify cases. 23% of the time-fixed studies scored zero 
stars in the relevant NOS item as they used retrospective case ascertainment using 
(International Classification of Disease) ICD codes or treatment.[120] 
3.1 Meta-analyses  
 
For the BSI meta-analysis two studies reported results for more than one organism.[27, 33] 
Five studies reported results for susceptible and resistant organisms separately.[27, 34, 37, 
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47, 50] Three studies reported results using more than one statistical method.[34, 48, 52] 
Time-fixed methods consistently produce higher estimates of HAI impact on LOS with larger 
confidence intervals. In the BSI meta-analysis the focus is on within-study differences and 
we found that the causative organism and susceptibility have a big impact on excess LOS 
due to HAI; these should always be taken into account when calculating the economic 
impact of BSI in different settings. 
Figure 5 presents the results of the meta-analysis in the BSI articles grouped by statistical 
method. There is considerable variability in the estimates with a range of 1.2 to 26.4 excess 
days due to HAI. Among studies that used more than one statistical method two studies 
show that estimated excess LOS can increase substantially if patient characteristics and 
comorbidities are ignored by using group comparison as opposed to regression or simple 
matching.[34, 48]  Vrijens et al show that ignoring BSI as a time-dependent event by using 
time-fixed methods more than doubles estimated excess LOS.[52] Heterogeneity is very high 
in every group with the matching on time group having the lowest I2 of 82%. One reason for 
the high heterogeneity is that these studies examine a range of organisms associated with 
BSI. Studies that did not estimate impact of specific organism but had access to laboratory 
results reported that S. aureus was one of the most common causes of BSI in their 
samples.[33, 40, 47, 52] Stewardson et al estimate the impact of susceptible and resistant 
Enterobacteriaceae and S. aureus BSI using multistate modelling and find that the estimated 
impact of the susceptible BSI infections on LOS approximately doubles when S. aureus is the 
causative agent.[27] The study by Barnett et al shows that BSI caused by Gram positive 
bacteria have a much greater impact on LOS than BSI caused by Gram negative bacteria.[33] 
Figure 5 shows that antimicrobial resistance (AMR) increases estimated LOS and there are 
noticeable differences between causative agents.[27, 33, 34, 50] The variability in the BSI 
studies contrasts to the second meta-analysis focusing on a single organism to isolate the 
impact of statistical method on the estimates.  
We extracted 19 estimates from 19 studies estimating excess LOS due to Healthcare 
Associated (HA) CDI in high income countries (Figure 6).[53-64, 66-72] The HA CDI studies 
focus on a single infection type caused by the same organism and estimates in each 
statistical group were homogenous as shown by the low I2 scores within each analysis group 
in Figure 6. The overall I2, which can be calculated by analysing studies as a single group, was 
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very high (99.7%) and resembled I2 scores in the BSI studies. Figure 6 shows that the results 
should be analysed separately for each statistical methodology. The CDI results display a 
large variability in LOS estimates on the impact of CDI with a range of 1 to 16 excess days. 
Since CDI is a commonly occurring HAI even a small number of extra days can have a 
significant impact on cost estimates due to CDI.[121] Time-fixed methods produce 
consistently higher estimates of excess LOS due to CDI. This finding is particularly evident in 
studies using regression methods and simple matching studies, which show higher 
heterogeneity and much higher and uncertain estimates of LOS when compared to time-
varying methods. The impact of BSI and CDI on LOS is consistently overestimated when 
time-fixed methods are used.  
4 Discussion 
This systematic review found that there are six main statistical techniques which have been 
used over the last 20 years to assess excess LOS due to HAI. These methods can be grouped 
in time-fixed and time-varying according to their treatment of time-dependence. We found 
a significant body of evidence that does not take into account the time-dependent nature of 
HAI by employing time-fixed methods. Even though time-varying methods appeared more 
than ten years ago the majority of articles in high income countries still use time-fixed 
methods to estimate excess LOS due to HAI. In middle income countries (where 
sophisticated data are not routinely collected due to funding constraints) we only identified 
one study that controls for time-dependence.[31]  
The ability to synthesise evidence from multiple studies is key if policymakers and 
researchers are willing to model the cost-effectiveness of IPC interventions. Despite a large 
number of publications on each type of infection it is challenging and sometimes 
inappropriate to synthesise evidence due to the fact researchers use different study designs, 
statistical methods and reporting styles. There are inherent difficulties in HAI literature 
because of the range of different infection types, settings, patient types, organisms and 
AMR. However, we found that papers often magnify these differences by using time-fixed 
methods. This limits our ability to synthesise evidence, even in cases where studies 
investigate a single HAI type or a single organism. When looking at a single infection (BSI) 
the meta-analysis has shown that causative organisms and antibiotic resistance have a large 
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impact on the excess LOS estimates. Where synthesising evidence appeared possible (CDI) 
meta-analysis showed that the choice of statistical method can have a highly distortive 
effect on excess LOS estimates. The meta-analysis of the BSI studies suggests that defining a 
high level infection type (such as BSI) is not sufficient to perform synthesis when trying to 
estimate economic impact since this can hide substantial heterogeneity between studies. So 
other than choosing studies that account for time-dependence bias it is also important to be 
clear about types of organism and AMR in the studies of the meta-analysis. The meta-
analysis of CDI studies confirmed previous work which suggests time-fixed methods 
overestimate the burden of HAI when compared to time-varying.[22] We suggest that 
researchers take into account all the above when performing meta-analysis to estimate 
economic cost of HAI. 
IPC planning at international, national or local levels requires accurate cost estimates and 
therefore excess LOS precision. IPC measures aim to prevent HAI cases in order to improve 
clinical effectiveness and maximise health benefits.[13] Identifying which combination of 
HAI and patient characteristics causes the greatest economic burden should help focus 
investment in interventions that give the greatest return. The main cost attributable to HAI 
is the additional stay in the hospital.[5, 7, 78, 122] The prevention of HAI can lead to 
released bed days, reduction in waiting times and the ability to treat more patients and that 
can be achieved through IPC interventions. Modelling studies that synthesise evidence from 
different sources can inform policy related to IPC measures.[123] Nevertheless, it is of the 
utmost importance that modelling studies are based on well-designed studies otherwise 
recommendations on cost-effectiveness of IPC interventions become unreliable.  
Our results agree with previous work, which suggests that estimates from time-varying 
methods that control for time-dependent bias should be adopted when making policy 
decisions.[7, 12, 13] Time-fixed methods suffer from time-dependent bias and studies 
employing such methods are of lower quality overall. Each study is conducted in inherently 
different circumstances with differences in characteristics of the study population and 
methodologies. There are also differences in the way LOS outcomes are reported 
complicating the process of synthesising results. Some studies were excluded from this 
review because it was not clear if cases were healthcare associated infection, colonisation, 
community acquired infection or a combination. Since IPC interventions are designed to 
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target HAI and not community onset infection, only studies that clearly show that outcomes 
are HAI-specific should be used for planning policy.   
There is already an acknowledged requirement for structured reporting of observational 
studies with the STROBE statement and economic evaluation studies with the CHEERS 
statement. Studies investigating HAI burden are observational studies which fall within the 
scope of STROBE.[124, 125] Analytical methodologies have evolved and reporting guidelines 
have not accounted for all these developments and should also be updated. Studies that 
fully meet the STROBE recommendations will not necessarily avoid time-dependent bias or 
measurement bias in their results. Our recommendation is that additional aspects of study 
design and reporting should be considered especially within studies reporting HAI and 
antimicrobial resistance.  
Overall recommendations are:  
1) Studies can have either a cohort or a case-control design but always ensure that the 
comparator group is clearly defined especially when reporting AMR outcomes.  
2) Studies should employ appropriate case definitions, ideally internationally 
recognised definitions applied to records and clearly distinguish between HAI and 
community-onset or colonisation.  
3) Studies should collect data on the timing of events and control for time-dependent 
bias by using a time varied analytical methodology 
4) Studies should report time-constant hazard rates from a simple multi-state model or 
if these are not available patient-days of HAI and non-HAI patients.  
5) Studies must clearly state if LOS was measured from admission to discharge or if LOS 
was partially measured e.g. LOS within ICU. 
 
This review indicates that excess LOS estimates based on statistical methods that treat HAI 
as a time-varying exposure show a shorter estimated extra stay. This means that HAI costs 
may have been overestimated.[5, 6, 10, 13, 22, 69, 126] Time-dependent bias and different 
statistical methods lead to highly variable estimates, which might lead to inefficient policies. 
Beyersmann et al show that time-dependant bias is large in methods such as regression 
methods and survival analysis that do not normally treat HAI as a time-varying 
exposure.[127] Common regression methods cannot control for the timing of events and 
caution should be exercised when applying or interpreting regression results.[128] 
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Regression methods to estimate excess LOS should only be used for associations rather than 
causal inference.[42] Survival analysis is normally a time-fixed method but it can be adapted 
and the 2 survival analysis studies that we have included in this review treat HAI as time-
varying.[59, 86]    
Matching methods should match on time to infection requiring the control patient to have 
spent an equivalent time in hospital before the infection as the case.[37, 52] This will not 
completely eliminate time-dependent bias but it will significantly reduce it. Nelson et al 
compare three estimation strategies and show that matching on the time to infection can 
substantially reduce time-dependence bias.[22] Matching on time to infection should be 
ideally performed by using incidence density sampling. This produces similar estimates to 
multistate modelling although with less precision and wider confidence intervals.[3] A 
combination of these two methods was used by Barnett et al who applied multistate 
modelling to a sample that was matched using incidence density sampling.[33]  The 
recommended approach to estimate excess LOS is multistate modelling.[4] Wolkewitz et al 
(2017) show that if information on event counts or patient days is available it is possible to 
perform basic multistate analysis with a pocket calculator.[129] A limitation of multistate 
models in the past was that they were not able to control for patient characteristics. 
Stewardson et al demonstrate an approach to indirectly control for age and comorbidities 
using a multilevel model.[27] In most cases HAI patients have greater severity of illness and 
comorbidities when compared with non-HAI patients. Since severity of illness and 
comorbidities are also predictors of LOS it is important to control for these because such 
variables may distort the relationship between infection and LOS.[17]  
One reason for the lack of studies that control for time-dependent bias may be the data 
requirements for these methods, e.g. knowing the day the infection began during a patient’s 
hospital stay. Only if this information is available can researchers employ statistical methods 
that control for time-dependent bias. We identified US studies that frequently use the 
National Inpatient Sample (NIS).[32, 36, 57, 58, 66, 72, 115, 119]  These studies use ICD 
codes to identify cases but NIS data do not provide information on the timing of infection 
forcing researchers to use time-fixed methods to estimate impact of HAI on LOS. These 
studies received the lowest scores in the quality assessment and estimates should be 
treated with caution. Barnett et al published a detailed description of how time-dependent 
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data can be organised for use in statistical models.[128] An estimate of only a few days 
excess stay in hospital can have a large impact on total cost. For example, the cost of an 
excess bed-day in 2015-2016 has been estimated at £306 and there were 1,398 CDI cases in 
2016 in Scotland.[130, 131] Every extra day of estimated excess LOS due to CDI would 
appear to cost an additional £427,788 to the Scottish NHS. We recognise that for this 
calculation we have not used unit costs that reflect the opportunity cost of the bed-day and 
these would be expected to be lower than £306.[132] Even though the exact figure can be 
challenged on the basis of not being a pure opportunity cost we have seen that time-fixed 
methods can overestimate this effect for CDI by up to seven times. Irrespective of using 
accounting or opportunity costs excess LOS should be estimated using time-varying 
methods.   
We propose that methods that minimise time-dependent bias are used to inform models of 
cost-effectiveness because only after establishing estimates through appropriate research 
methods can we combine findings from multiple studies to inform policy decisions. 
Following the recommendations of this review would improve our ability to undertake both 
meta-analysis and modelling studies. This will help to develop more precise estimates of the 
effects of interventions by ensuring use of studies with as low bias as possible especially 
measurement and time-dependent bias. In general, more and better designed studies are 
needed in order to provide accurate data to support effective and efficient IPC 
interventions.[14]   
5 Conclusions 
 
Accurate quantification of additional costs of HAI is essential for developing cost-effective 
IPC measures. A range of statistical analyses have been used to address the question of 
excess LOS as a result of HAI. Availability of specific data item and study design can dictate 
researchers’ ability to employ time-varying statistical techniques.   As with all research that 
requires data collection there is a balance to be struck in terms of resource intensive data 
collection and requirements for analysis. When measuring economic impact, a major 
component of HAI costs can be captured by measuring the additional LOS due to these 
infections. We recommend that studies collect accurate information on the timing of key 
17 
 
events such as time of admission, time of infection and time of discharge. Combining this 
information with patient characteristics and co-morbidities with appropriate statistical 
methods such as survival analysis; multistate modelling; or matching on time to infection 
minimises bias when estimating impact on LOS. Better study design, analytical techniques 
and reporting are needed to improve the quality of evidence worldwide. Further research is 
needed to identify the impact of HAI, including in middle and low income countries where 
data availability is limited due to funding constraints.[133]  
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Tables 
Table I: Summary of characteristics of published studies that produced estimates of excess LOS due to HAI. Where 
studies reported more than one HAI type we extracted all LOS estimates.  
Study Characteristics  
  
HAI type(s) Reported: No of studies (%) of studies 
Bloodstream 23 (19%) 
Gastro-intestinal 22 (18%) 
Surgical site 27 (22%) 
HAI*  26 (22%) 
Urinary tract 10 (8%) 
Pneumonia 8 (7%) 
Lower respiratory tract  4 (3%) 
Bone and joint  1 (1%) 
 
Primary Statistical Methodology: 
Time-Fixed 
Group Comparison 14 (15%) 
Matching (Simple) 31 (34%) 
Regression 24 (26%) 
Time-varying 
Matching (Time) 12 (13%) 
Survival Analysis 2 (2%) 
Multistate Model 9 (10%) 
Total 92 (100%) 
 
Included Studies by Country and Income Classification: 
High Income 81 (88%) 
Middle Income 11 (12%) 
Study Design 
Case-Control 18 (20%) 
Cohort 74 (80%) 
   
Studies’ Year of Data Collection** 
1989-2000 38  
2001-2004 37  
2005-2008 54  
2009-2012 43  
2013-2016 10  
* HAI refers to studies which estimated total impact on LOS across more than one type of HAI or multiple types of HAI due 
to a single organism (e.g. MRSA). 
**Counted if contain any data collected in these years (most studies used data collected in multiple years) 
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Figure 1: PRISMA Flow Diagram showing the relevant observational studies of the impact of HAI on LOS 
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Figure 2: Articles by year of publication and statistical method. Number of studies published in the corresponding year 
are shown below each bar. Group comparison, Matching (Simple) and Regression are time-fixed methods. Matching 
(Time), Survival Analysis and Multistate Modelling are time-varying methods.    
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Figure 3 Articles by year of publication and time-fixed vs time-varying methodologies.  
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Figure 4:  Quality assessment by type of statistical method. Papers quality assessed using the NOS assessment tool for 
case-control and cohort studies. Studies could get a maximum of 8 stars. 120 LOS estimates quality assessed in 91 
studies. Number of estimates assessed in each statistical method are shown on the bottom of each bar. Mean NOS stars 
by method are shown below each bar. There were three LOS estimates in the Survival Analysis group which were 
allocated a perfect score of 8 stars. Error bars calculated from standard deviations. Group comparison, Matching 
(Simple) and Regression are time-fixed methods. Matching (Time), Survival Analysis and Multistate Modelling are time-
varying methods.    
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Figure 5: Excess days and 95% CIs for the association of LOS and BSI. The triangles and horizontal lines correspond to the 
study-specific Excess Days estimates and 95% CIs. The diamonds represent the pooled Excess Days and 95% CIs of each 
subgroup. The vertical solid line shows Excess Days of zero. Mixed: Range of organisms included, not separated by 
antimicrobial resistance. VRE: Vancomycin-resistant enterococci. VSE: Vancomycin-susceptible enterococci. CNS: 
Coagulase-negative staphylococci. MRSA: Methicillin-resistant Staphylococcus aureus. MSSA: Methicillin-susceptible 
Staphylococcus aureus. Gram+: Gram-positive bacteria. Gram-: Gram-negative bacteria. ESBL+:  Extended-Spectrum β-
Lactamase–Producing Enterobacteriaceae positive. ESBL-:  Extended-Spectrum β-Lactamase–Producing 
Enterobacteriaceae negative. 3GCRE: Third-generation cephalosporin resistant Enterobacteriaceae. 3GCSE: Third-
generation cephalosporin susceptible Enterobacteriaceae. Enterococci: Susceptible and resistant enterococcal BSI. 
Acinetobacter: Susceptible and resistant Acinetobacter BSI. Group comparison, Matching (Simple) and Regression are 
time-fixed methods. Matching (Time), Survival Analysis and Multistate Modelling are time-varying methods.     
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Figure 6: Excess days and 95% CIs for the association of LOS and CDI. The triangles and horizontal lines correspond to the 
study-specific Excess Days estimates and 95% CIs. The diamonds represent the pooled Excess Days and 95% CIs of each 
subgroup and overall population. The vertical solid line shows Excess Days of zero. Group comparison, Matching 
(Simple) and Regression are time-fixed methods. Matching (Time), Survival Analysis and Multistate Modelling are time-
varying methods.    
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Figure Legends 
Figure 7: PRISMA Flow Diagram showing the relevant observational studies of the impact of HAI on LOS 
Figure 8: Articles by year of publication and statistical method. Number of studies published in the corresponding year 
are shown below each bar. Group comparison, Matching (Simple) and Regression are time-fixed methods. Matching 
(Time), Survival Analysis and Multistate Modelling are time-varying methods.    
Figure 9 Articles by year of publication and time-fixed vs time-varying methodologies.  
Figure 10:  Quality assessment by type of statistical method. Papers quality assessed using the NOS assessment tool for 
case-control and cohort studies. Studies could get a maximum of 8 stars. 120 LOS estimates quality assessed in 91 
studies. Number of estimates assessed in each statistical method are shown on the bottom of each bar. Mean NOS stars 
by method are shown below each bar. There were three LOS estimates in the Survival Analysis group which were 
allocated a perfect score of 8 stars. Error bars calculated from standard deviations. Group comparison, Matching 
(Simple) and Regression are time-fixed methods. Matching (Time), Survival Analysis and Multistate Modelling are time-
varying methods.    
Figure 11: Excess days and 95% CIs for the association of LOS and BSI. The triangles and horizontal lines correspond to 
the study-specific Excess Days estimates and 95% CIs. The diamonds represent the pooled Excess Days and 95% CIs of 
each subgroup. The vertical solid line shows Excess Days of zero. Mixed: Range of organisms included, not separated by 
antimicrobial resistance. VRE: Vancomycin-resistant enterococci. VSE: Vancomycin-susceptible enterococci. CNS: 
Coagulase-negative staphylococci. MRSA: Methicillin-resistant Staphylococcus aureus. MSSA: Methicillin-susceptible 
Staphylococcus aureus. Gram+: Gram-positive bacteria. Gram-: Gram-negative bacteria. ESBL+:  Extended-Spectrum β-
Lactamase–Producing Enterobacteriaceae positive. ESBL-:  Extended-Spectrum β-Lactamase–Producing 
Enterobacteriaceae negative. 3GCRE: Third-generation cephalosporin resistant Enterobacteriaceae. 3GCSE: Third-
generation cephalosporin susceptible Enterobacteriaceae. Enterococci: Susceptible and resistant enterococcal BSI. 
Acinetobacter: Susceptible and resistant Acinetobacter BSI. Group comparison, Matching (Simple) and Regression are 
time-fixed methods. Matching (Time), Survival Analysis and Multistate Modelling are time-varying methods.     
Figure 12: Excess days and 95% CIs for the association of LOS and CDI. The triangles and horizontal lines correspond to 
the study-specific Excess Days estimates and 95% CIs. The diamonds represent the pooled Excess Days and 95% CIs of 
each subgroup and overall population. The vertical solid line shows Excess Days of zero. Group comparison, Matching 
(Simple) and Regression are time-fixed methods. Matching (Time), Survival Analysis and Multistate Modelling are time-
varying methods.    
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Supplementary Material 1 
Studies eligible for data extraction and analysis by HAI type. Note that some studies appear in more than one HAI type. 
 
Authors Study Design 
Primary Statistical 
Methodology 
Country QA Stars 
Bloodstream Infection 
Riu et al (2016)[47] Retrospective cohort Group comparison Spain 6 
Al-Rawajfah et al (2012)[32] Retrospective case-control Matching (Simple) USA 4 
Caballero-Granado et al 
(2001)[35] 
Prospective case-control Matching (Simple) Spain 6 
Kothari et al (2009)[41] Retrospective case-control Matching (Simple) India 7 
Molina et al (2013)[42] Prospective case-control Matching (Simple) Spain 7 
Peng et al (2006)[43] Retrospective cohort Matching (Simple) USA 7 
Primo et al (2012)[45] Retrospective case-control Matching (Simple) Brazil 5 
Song et al (2003)[49] Retrospective cohort Matching (Simple) USA 6 
Butler et al (2010)[34] Retrospective cohort Regression USA 6 
Dasenbrock et al (2016)[36] Retrospective cohort Regression USA 5 
Plowman et al (2001)[44] Prospective cohort Regression UK 6 
Rattanaumpawan et al (2017)[46] Retrospective cohort Regression Thailand 7 
Roberts et al (2010)[48] Retrospective cohort Regression USA 7 
Al-Rawajfah et al (2013)[31] Retrospective case-control Matching (Time) Jordan 7 
de Kraker et al (2011)[37] Prospective cohort Matching (Time) Europe 7 
Glied et al (2016)[38] Retrospective cohort Matching (Time) USA 8 
Grupper et al (2007)[39] Retrospective cohort Matching (Time) Israel 6 
Kaye et al (2014)[40] Retrospective cohort Matching (Time) USA 8 
Vrijens et al (2010)[52] Retrospective cohort Matching (Time) Belgium 8 
Vrijens et al (2012)[51] Retrospective cohort Matching (Time) Belgium 8 
Barnett et al (2013)[33] Retrospective case-control Multistate Modelling Australia 7 
Stewardson et al (2013)[50] Retrospective cohort Multistate Modelling Switzerland 8 
Stewardson et al (2016)[27] Retrospective cohort Multistate Modelling Europe 7 
Gastrointestinal Infection 
Abdelsattar et al (2015)[53] Prospective cohort Group comparison USA 5 
Skovrlj et al (2014)[66] Retrospective cohort Group comparison USA 3 
Zhang et al (2016)[73] Prospective cohort Group comparison China 5 
Bond et al (2017)[54] Prospective case-control Matching (Simple) Australia 7 
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Egorova et al (2015)[57] Retrospective cohort Matching (Simple) USA 5 
Flagg et al (2014)[58] Retrospective cohort Matching (Simple) USA 5 
Keshavamurthy et al (2014)[61] Prospective cohort Matching (Simple) USA 7 
Pakyz et al (2011)[64] Retrospective case-control Matching (Simple) USA 4 
Chen et al (2017)[55] Retrospective cohort Regression Australia 6 
Eckmann et al (2013)[56] Retrospective cohort Regression UK 7 
Lipp et al (2012)[62] Retrospective cohort Regression USA 5 
Yasunaga et al (2012)[71] Retrospective cohort Regression Japan 5 
Zerey et al (2007)[72] Retrospective cohort Regression USA 5 
Jacob et al (2017)[60] Retrospective cohort Matching (Time) USA 8 
Ryan et al (2017)[65] Retrospective cohort Matching (Time) Ireland 7 
Tabak et al (2013)[68] Retrospective cohort Matching (Time) USA 8 
Vonberg et al (2008)[70] Prospective case-control Matching (Time) Germany 7 
Vrijens et al (2012)[51] Retrospective cohort Matching (Time) Belgium 8 
Foster et al (2012)[59] Retrospective cohort Survival Analysis Canada 8 
Mitchell et al (2014)[63] Retrospective cohort Multistate Modelling Australia 6 
Stevens et al (2015)[67] Retrospective cohort Multistate Modelling USA 8 
van Kleef et al (2014)[69] Prospective cohort Multistate Modelling UK 8 
Surgical Site Infection 
Kuy et al (2014)[89] Retrospective cohort Group comparison USA 5 
Lamarsalle et al (2013)[90] Retrospective cohort Group comparison France 4 
Anderson et al (2009)[74] Prospective case-control Matching (Simple) USA 7 
Apisarnthanarak et al (2003)[75] Prospective case-control Matching (Simple) USA 7 
Atkinson et al (2017)[77] Prospective cohort Matching (Simple) UK 6 
Coskun et al (2005)[79] Prospective cohort Matching (Simple) Turkey 6 
Delgado-Rodriguez et al 
(1997)[81] 
Prospective cohort Matching (Simple) Spain 7 
Gaine et al (2000)[83] Prospective case-control Matching (Simple) UK 6 
Gonzalez-Velez et al (2016)[85] Prospective case-control Matching (Simple) Spain 7 
Jenks et al (2014)[87] Retrospective cohort Matching (Simple) UK 7 
Kusachi et al (2012)[88] Prospective case-control Matching (Simple) Japan 7 
Merle et al (2000)[92] Prospective cohort Matching (Simple) France 7 
Monge Jodra et al (2006)[93] Prospective case-control Matching (Simple) Spain 7 
Olsen et al (2010)[94] Retrospective cohort Matching (Simple) USA 5 
Peng et al (2006)[43] Retrospective cohort Matching (Simple) USA 7 
Pollard et al (2006)[95] Retrospective cohort Matching (Simple) UK 5 
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Asensio and Torres (1999)[76] Retrospective cohort Regression Spain 7 
Boltz et al (2011)[78] Prospective cohort Regression USA 7 
Fukuda et al (2012)[82] Retrospective cohort Regression Japan 7 
Geubbels et al (2000)[84] Prospective cohort Regression Netherlands 6 
McGarry et al (2004)[91] Prospective cohort Regression USA 7 
Plowman et al (2001)[44] Prospective cohort Regression UK 7 
Roberts et al (2010)[48] Retrospective cohort Regression USA 7 
Glied et al (2016)[38] Retrospective cohort Matching (Time) USA 8 
Vrijens et al (2012)[51] Retrospective cohort Matching (Time) Belgium 8 
Herwaldt et al (2006)[86] Prospective cohort Survival Analysis USA 8 
De Angelis et al (2011)[80] Prospective cohort Multistate Modelling Switzerland 8 
Healthcare Associated Infection 
Dulworth and Pyenson (2004)[98] Retrospective cohort Group comparison USA 4 
Grandini and Caramelli (2006)[99] Retrospective cohort Group comparison Brazil 6 
Kollef et al (1997)[105] Prospective cohort Group comparison USA 5 
Nosrati et al (2010)[109] Prospective cohort Group comparison Iran 6 
Chacko et al (2017)[97] Prospective cohort Group comparison India 4 
O'Keefe et al (2017)[110] Retrospective cohort Group comparison Canada 5 
Delgado-Rodriguez et al 
(1997)[81] 
Prospective cohort Matching (Simple) Spain 7 
Khan and Celik (2001)[104] Prospective cohort Matching (Simple) Turkey 6 
Resch et al (2009)[111] Retrospective cohort Matching (Simple) Germany 5 
Karagozian et al (2010)[103] Retrospective cohort Matching (Simple) USA 7 
Wu et al (2008)[113] Retrospective cohort Matching (Simple) USA 5 
Campbell et al (2015)[96] Retrospective cohort Regression USA 6 
Graves et al (2007)[100] Prospective cohort Regression Australia 7 
Hassan et al (2010)[101] Retrospective cohort Regression USA 5 
Hoogervorst-Schilp et al 
(2015)[102] 
Retrospective cohort Regression Netherlands 6 
Lee et al (2011)[106] Retrospective cohort Regression Japan 5 
Lloyd-Smith et al (2013)[107] Retrospective case-control Regression Canada 5 
Plowman et al (2001)[44] Prospective cohort Regression UK 6 
Roberts et al (2010)[48] Retrospective cohort Regression USA 7 
Trybou et al (2013)[112] Retrospective cohort Regression Belgium 7 
Nelson et al (2015)[22]  Retrospective cohort Matching (Time) USA 8 
Vrijens et al (2012)[51] Retrospective cohort Matching (Time) Belgium 8 
Herwaldt et al (2006)[86] Prospective cohort Survival Analysis USA 8 
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Arefian et al (2016)[4] Prospective cohort Multistate Modelling Germany 7 
De Angelis et al (2011)[80] Prospective cohort Multistate Modelling Switzerland 8 
Macedo-Viñas et al (2013)[108] Retrospective cohort Multistate Modelling Switzerland 7 
Urinary Tract Infection 
Delgado-Rodriguez et al 
(1997)[81] 
Prospective cohort Matching (Simple) Spain 7 
Peng et al (2006)[43] Retrospective cohort Matching (Simple) USA 7 
Dasenbrock et al (2016)[36] Retrospective cohort Regression USA 5 
Ingeman et al (2011)[114] Retrospective cohort Regression Denmark 5 
Nosova et al (2013)[115] Retrospective cohort Regression USA 5 
Plowman et al (2001)[44] Prospective cohort Regression UK 7 
Rattanaumpawan et al (2017)[46] Retrospective cohort Regression Thailand 7 
Roberts et al (2010)[48] Retrospective cohort Regression USA 7 
Glied et al (2016)[38] Retrospective cohort Matching (Time) USA 8 
Vrijens et al (2012)[51] Retrospective cohort Matching (Time) Belgium 8 
Pneumonia 
Zhang and Duan (2015)[118] Prospective cohort Group comparison China 4 
Micek et al (2016)[116] Retrospective case-control Matching (Simple) USA 6 
Peng et al (2006)[43] Retrospective cohort Matching (Simple) USA 7 
Restrepo et al (2010)[117] Retrospective cohort Matching (Simple) USA 6 
Dasenbrock et al (2016)[36] Retrospective cohort Regression USA 5 
Ingeman et al (2011)[114] Retrospective cohort Regression Denmark 5 
Roberts et al (2010)[48] Retrospective cohort Regression USA 7 
Glied et al (2016)[38] Retrospective cohort Matching (Time) USA 8 
Lower Respiratory Tract Infection (other than pneumonia) 
Delgado-Rodriguez et al 
(1997)[81] 
Prospective cohort Matching (Simple) Spain 7 
Graves et al (2007)[100] Prospective cohort Regression Australia 7 
Plowman et al (2001)[44] Prospective cohort Regression UK 7 
Vrijens et al (2012)[51] Retrospective cohort Matching (Time) Belgium 8 
Bone and Joint Infection 
Padegimas et al (2015)[119] Retrospective cohort Group comparison USA 4 
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Supplementary Material 2 
The PubMed search strategy is presented in three parts. The first part has cross-infection 
keywords and Mesh terms. The second part has HAI related keywords and Mesh terms. The 
third part has economic and length of stay keywords and Mesh terms.  
Cross Infection 
 ((“Cross Infection”[Mesh] OR (cross infection*[tiab]) OR (healthcare associated infection*[tiab]) OR (health 
care associated infection*[tiab]) OR (hospital acquired infection*[tiab]) OR (hospital-acquired 
infection*[tiab]) OR (hospital associated infection*[tiab]) OR (healthcare-associated infection*[tiab]) OR 
(healthcare acquired infection*[tiab]) OR (health care acquired infection*[tiab]) OR (nosocomia*[tiab]) OR 
“Disease Transmission, Infectious”[Mesh] OR (cross transmission[tiab]) OR (infectious disease 
transmission[tiab]))  
Healthcare Associated Infections 
(“Catheter-Related Infections”[Mesh] OR (catheter related infection*[tiab]) OR (catheter acquired 
infection*[tiab]) OR (catheter associated infection*[tiab]) OR (CAUTI[tiab]) OR (device related 
infection*[tiab]) OR (device acquired infection*[tiab]) OR (device associated infection*[tiab]) OR (central 
line related bloodstream infection*[tiab]) OR (central line acquired bloodstream infection*[tiab]) OR 
(central line associated bloodstream infection*[tiab]) OR (CLABSI[tiab]) OR(CRBSI[tiab]) OR 
“bacteremia”[Mesh] OR (bacteremia[tiab]) OR “Methicillin-Resistant Staphylococcus aureus”[Mesh] OR 
"Clostridium difficile"[Mesh] OR "Clostridium Infections"[Mesh] OR "Enterocolitis, 
Pseudomembranous"[Mesh] OR (Clostridium difficile[tiab]) OR (c. diff*[tiab]) OR (CDI[tiab]) OR (CDAD[tiab]) 
OR (gastrointestinal infection*[tiab]) OR “norovirus”[Mesh] OR "Pneumonia, Ventilator-Associated"[Mesh] 
OR “Respiratory Tract Infections”[Mesh] OR (ventilator acquired pneumonia[tiab]) OR (nosocomial 
pneumonia[tiab]) OR (ventilator associated pneumonia[tiab]) OR “sepsis”[Mesh] OR "Urinary Tract 
Infections"[Mesh] OR "Urinary Catheterization"[Mesh] OR (urinary catheter*[tiab]) OR "Surgical Wound 
Infection"[Mesh] OR (surgical site infection*[tiab]) OR (postoperative infection*[tiab]) OR (postsurgical 
infection*[tiab]) OR (wound infection*[tiab]) OR (sternal wound infection*[tiab]) OR (postoperative[tiab]) 
OR (post-surgical[tiab]) OR “Cardiovascular Infections”[Mesh] OR “endocarditis, bacterial”[Mesh] OR 
(cardiovascular infection*[tiab]) OR (endocarditis[tiab]) OR (pericarditis[tiab]) OR “Staphylococcal Skin 
Infections”[Mesh] OR (skin infection*[tiab]) OR (soft tissue infection*[tiab]) OR “Osteomyelitis”[Mesh] OR 
(bone infection*[tiab]) OR (joint infection*[tiab]) OR “central nervous system infections”[Mesh] OR “eye 
infections”[Mesh] OR (eye infection*[tiab]) OR “otitis”[Mesh] OR ear infection*[tiab] OR “Sinusitis”[Mesh] 
OR (mouth infection*[tiab]) OR “reproductive tract infections”[Mesh] OR (reproductive tract 
infection*[tiab])))  
Economics and length of stay 
("Costs and Cost Analysis"[Mesh] OR "Health Care Costs"[Mesh] OR "Health Expenditures"[Mesh] OR 
"Direct Service Costs"[Mesh] OR "Hospital Costs"[Mesh] OR "Employer Health Costs"[Mesh] OR "Drug 
Costs"[Mesh] OR "Cost of Illness"[Mesh] OR "Economics"[Mesh] OR "Length of Stay"[Mesh] OR (length of 
stay[tiab]) OR (length of hospitalization[tiab]) OR (hospitalization length[tiab]) OR (duration of stay[tiab]))  
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Supplementary Material 3 
Newcastle-Ottawa quality assessment tool 
This scale has been adapted from the Newcastle-Ottawa Quality Assessment Scale to 
perform quality assessment (QA) in the systematic review. In this version of NOS we define 
the exposure as HAI and the outcome as discharge or total duration of hospital stay.  
COHORT STUDIES 
Selection: (Maximum 5 stars) 
1) Representativeness of the sample: 
a) Truly representative of the average in the target population (e.g. inpatient hospital 
specialty)**    
b) Somewhat representative of the average in the target population*  
c) Selected group of users. 
d) No description of the sampling strategy. 
 
2) Sample size: 
              a) Adequate sample size to be able to draw conclusions about impact* 
              b) Very small sample size. 
 
3) Ascertainment of the exposure: 
a) Case definitions applied to records (eg electronic medical records, microbiology 
results)** 
b) Nurses, doctors or laboratory tests only to identifying exposure*  
c) Exposure assumed retrospectively purely due to treatment (i.e. antibiotics) or with ICD 
codes 
d) written, self-reported or self-assessed  
e) no description 
 
continues next page 
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Comparability: (Maximum 1 stars) 
 
1) The subjects in different outcome groups are comparable, based on the study design or analysis. 
Confounding factors are controlled. 
                a) The study controls for additional factors (such as age, comorbidities, device use/not an 
exhaustive list of factors)* 
                b) The study does not control for additional factors.  
 
 
Outcome: (Maximum 2 stars) 
1) Assessment of the outcome: 
                a) Clearly reported total duration of hospitalisation* 
                b) Duration of hospitalisation is reported but unclear if it refers to total. 
 
2) HAI treated as a time-dependent exposure: 
                a) The statistical methods used to analyse the data control for bias that can occur if baseline 
immeasurable time-dependent factors that cannot be recorded at baseline and 
change value after patient observation starts are analysed as if they were known and 
available at baseline.* 
                b) The statistical methods do not treat HAI as a time-dependent exposure.  
 
 
 
For case-control studies use items on next page 
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CASE-CONTROL STUDIES 
Adapted from the Newcastle-Ottawa Quality Assessment Scale. Cases refer to HAI patients 
and control patients refer to non-HAI patients.  
Selection: (Maximum 5 stars) 
1) Is the case definition adequate? 
a) Case definitions applied to records (eg electronic medical records, microbiology results)** 
b) Nurses, doctors or laboratory tests only to identifying exposure*  
c) Exposure assumed retrospectively purely due to treatment (i.e. antibiotics) or with ICD codes 
d) written, self-reported or self-assessed  
e) no description 
 
2) Representativeness of the cases 
a) consecutive or obviously representative series of cases*   
b) potential for selection biases or not stated 
3) Selection of Controls 
a) controls from same target population chosen prospectively** 
b) controls from diverse population chosen retrospectively*   
c) no description 
 
Comparability (Maximum 1 stars) 
1) Comparability of cases and controls on the basis of the design or analysis 
 a) The study controls for additional factors.* 
 b) The study does not control for additional factors. 
 
 
Outcome (Maximum 2 stars) 
 
1) Assessment of the outcome: 
                a) Clearly reported total duration of hospitalisation* 
                b) Duration of hospitalisation is reported but unclear if it refers to total. 
 
2)   HAI treated as a time-dependent exposure: 
                a) The statistical methods used to analyse the data control for bias that can occur if baseline 
immeasurable time-dependent factors that cannot be recorded at baseline and 
change value after patient observation starts are analysed as if they were known and 
available at baseline.* 
                b) The statistical methods do not treat HAI as a time-dependent exposure. 
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Supplementary Material 4 
Table shows quality assessment breakdown for each study. Quality assessment was performed with the Newcastle-Ottawa Scale (NOS). 
Headings on table are named after items in the cohort/case control versions of NOS where applicable.  Each study could be awarded a 
maximum of 8 stars.  
Authors 
Sample 
representative/Case 
definitions adequate 
Sample 
size/Representativeness 
of cases 
Ascertainment of 
exposure/Selection 
controls 
Study controls for 
additional factors 
Assessment of 
outcome 
HAI treated as a time 
varying exposure 
Total 
Bloodstream Infection 
Riu et al (2016)[47] 2 1 2 0 1 0 6 
Al-Rawajfah et al (2012)[32] 0 1 1 1 1 0 4 
Caballero-Granado et al (2001)[35] 2 1 2 0 1 0 6 
Kothari et al (2009)[41] 2 1 2 1 1 0 7 
Molina et al (2013)[42] 2 1 2 1 1 0 7 
Peng et al (2006)[43] 2 1 2 1 1 0 7 
Primo et al (2012)[45] 2 1 1 0 1 0 5 
Song et al (2003)[49] 2 1 2 0 1 0 6 
Butler et al (2010)[34] 2 1 1 1 1 0 6 
Dasenbrock et al (2016)[36] 2 1 0 1 1 0 5 
Plowman et al (2001)[44] 2 0 2 1 1 0 6 
Rattanaumpawan et al (2017)[46] 2 1 2 1 1 0 7 
Roberts et al (2010)[48] 2 1 2 1 1 0 7 
Al-Rawajfah et al (2013)[31] 2 1 1 1 1 1 7 
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de Kraker et al (2011)[37] 2 1 1 1 1 1 7 
Glied et al (2016)[38] 2 1 2 1 1 1 8 
Grupper et al (2007)[39] 2 0 1 1 1 1 6 
Kaye et al (2014)[40] 2 1 2 1 1 1 8 
Vrijens et al (2010)[52] 2 1 2 1 1 1 8 
Vrijens et al (2012)[51] 2 1 2 1 1 1 8 
Barnett et al (2013)[33] 2 1 1 1 1 1 7 
Stewardson et al (2013)[50] 2 1 2 1 1 1 8 
Stewardson et al (2016)[27] 2 1 1 1 1 1 7 
Gastrointestinal Infection 
Abdelsattar et al (2015)[53] 2 1 1 0 1 0 5 
Skovrlj et al (2014)[66] 2 1 0 0 0 0 3 
Zhang et al (2016)[73] 2 1 1 0 1 0 5 
Bond et al (2017)[54] 2 1 2 1 1 0 7 
Egorova et al (2015)[57] 2 1 0 1 1 0 5 
Flagg et al (2014)[58] 2 1 0 1 1 0 5 
Keshavamurthy et al (2014)[61] 2 1 2 1 1 0 7 
Pakyz et al (2011)[64] 0 1 1 1 1 0 4 
Chen et al (2017)[55] 2 1 1 1 1 0 6 
Eckmann et al (2013)[56] 2 1 2 1 1 0 7 
Lipp et al (2012)[62] 2 1 0 1 1 0 5 
Yasunaga et al (2012)[71] 2 1 0 1 1 0 5 
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Zerey et al (2007)[72] 2 1 0 1 1 0 5 
Jacob et al (2017)[60] 2 1 2 1 1 1 8 
Ryan et al (2017)[65] 2 1 1 1 1 1 7 
Tabak et al (2013)[68] 2 1 2 1 1 1 8 
Vonberg et al (2008)[70] 1 1 2 1 1 1 7 
Vrijens et al (2012)[51] 2 1 2 1 1 1 8 
Foster et al (2012)[59] 2 1 2 1 1 1 8 
Mitchell et al (2014)[63] 2 1 1 0 1 1 6 
Stevens et al (2015)[67] 2 1 2 1 1 1 8 
van Kleef et al (2014)[69] 2 1 2 1 1 1 8 
Surgical Site Infection 
Kuy et al (2014)[89] 2 0 2 0 1 0 5 
Lamarsalle et al (2013)[90] 2 1 0 0 1 0 4 
Anderson et al (2009)[74] 2 1 2 1 1 0 7 
Apisarnthanarak et al (2003)[75] 2 1 2 1 1 0 7 
Atkinson et al (2017)[77] 2 0 2 1 1 0 6 
Coskun et al (2005)[79] 2 0 2 1 1 0 6 
Delgado-Rodriguez et al (1997)[81] 2 1 2 1 1 0 7 
Gaine et al (2000)[83] 1 1 2 1 1 0 6 
Gonzalez-Velez et al (2016)[85] 2 1 2 1 1 0 7 
Jenks et al (2014)[87] 2 1 2 1 1 0 7 
Kusachi et al (2012)[88] 2 1 2 1 1 0 7 
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Merle et al (2000)[92] 2 1 2 1 1 0 7 
Monge Jodra et al (2006)[93] 2 1 2 1 1 0 7 
Olsen et al (2010)[94] 2 1 0 1 1 0 5 
Peng et al (2006)[43] 2 1 2 1 1 0 7 
Pollard et al (2006)[95] 2 0 1 1 1 0 5 
Asensio and Torres (1999)[76] 2 1 2 1 1 0 7 
Boltz et al (2011)[78] 2 1 2 1 1 0 7 
Fukuda et al (2012)[82] 2 1 2 1 1 0 7 
Geubbels et al (2000)[84] 2 1 1 1 1 0 6 
McGarry et al (2004)[91] 2 1 2 1 1 0 7 
Plowman et al (2001)[44] 2 1 2 1 1 0 7 
Roberts et al (2010)[48] 2 1 2 1 1 0 7 
Glied et al (2016)[38] 2 1 2 1 1 1 8 
Vrijens et al (2012)[51] 2 1 2 1 1 1 8 
Herwaldt et al (2006)[86] 2 1 2 1 1 1 8 
De Angelis et al (2011)[80] 2 1 2 1 1 1 8 
Healthcare Associated Infection 
Dulworth and Pyenson (2004)[98] 2 1 0 0 1 0 4 
Grandini and Caramelli (2006)[99] 2 1 2 0 1 0 6 
Kollef et al (1997)[105] 2 0 2 0 1 0 5 
Nosrati et al (2010)[109] 2 1 2 0 1 0 6 
Chacko et al (2017)[97] 2 0 1 0 1 0 4 
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O'Keefe et al (2017)[110] 2 1 1 0 1 0 5 
Delgado-Rodriguez et al (1997)[81] 2 1 2 1 1 0 7 
Khan and Celik (2001)[104] 2 1 1 1 1 0 6 
Resch et al (2009)[111] 2 1 0 1 1 0 5 
Karagozian et al (2010)[103] 2 1 2 1 1 0 7 
Wu et al (2008)[113] 2 1 0 1 1 0 5 
Campbell et al (2015)[96] 2 1 1 1 1 0 6 
Graves et al (2007)[100] 2 1 2 1 1 0 7 
Hassan et al (2010)[101] 2 1 0 1 1 0 5 
Hoogervorst-Schilp et al 
(2015)[102] 
2 1 1 1 1 0 6 
Lee et al (2011)[106] 2 1 0 1 1 0 5 
Lloyd-Smith et al (2013)[107] 1 1 1 1 1 0 5 
Plowman et al (2001)[44] 2 1 1 1 1 0 6 
Roberts et al (2010)[48] 2 1 2 1 1 0 7 
Trybou et al (2013)[112] 2 1 2 1 1 0 7 
Nelson et al (2015)[22] 2 1 2 1 1 1 8 
Vrijens et al (2012)[51] 2 1 2 1 1 1 8 
Herwaldt et al (2006)[86] 2 1 2 1 1 1 8 
Arefian et al (2016)[4] 2 1 2 0 1 1 7 
De Angelis et al (2011)[80] 2 1 2 1 1 1 8 
Macedo-Viñas et al (2013)[108] 2 1 1 1 1 1 7 
Urinary Tract Infection 
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Delgado-Rodriguez et al (1997)[81] 2 1 2 1 1 0 7 
Peng et al (2006)[43] 2 1 2 1 1 0 7 
Dasenbrock et al (2016)[36] 2 1 0 1 1 0 5 
Ingeman et al (2011)[114] 2 1 0 1 1 0 5 
Nosova et al (2013)[115] 2 1 0 1 1 0 5 
Plowman et al (2001)[44] 2 1 2 1 1 0 7 
Rattanaumpawan et al (2017)[46] 2 1 2 1 1 0 7 
Roberts et al (2010)[48] 2 1 2 1 1 0 7 
Glied et al (2016)[38] 2 1 2 1 1 1 8 
Vrijens et al (2012)[51] 2 1 2 1 1 1 8 
Pneumonia 
Zhang and Duan (2015)[118] 2 0 1 0 1 0 4 
Micek et al (2016)[116] 2 1 1 1 1 0 6 
Peng et al (2006)[43] 2 1 2 1 1 0 7 
Restrepo et al (2010)[117] 2 1 1 1 1 0 6 
Dasenbrock et al (2016)[36] 2 1 0 1 1 0 5 
Ingeman et al (2011)[114] 2 1 0 1 1 0 5 
Roberts et al (2010)[48] 2 1 2 1 1 0 7 
Glied et al (2016)[38] 2 1 2 1 1 1 8 
Lower Respiratory Tract Other Infection 
Delgado-Rodriguez et al (1997)[81] 2 1 2 1 1 0 7 
Graves et al (2007)[100] 2 1 2 1 1 0 7 
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Plowman et al (2001)[44] 2 1 2 1 1 0 7 
Vrijens et al (2012)[51] 2 1 2 1 1 1 8 
Bone and Joint Infection 
Padegimas et al (2015)[119] 2 1 0 0 1 0 4 
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Supplementary Material 5 
Details of Statistical Methods in the Systematic Review 
Statistical Method Description  Advantages Disadvantages Studies 
Group Comparison Naive comparison of means 
between an infected and an 
uninfected group. Simple method 
of analysis that takes advantage 
of raw data. The groups may not 
be similar due to differing 
characteristics (e.g. age, 
comorbidities) of patients in the 
HAI group. 
Easy to use and only requires very 
basic data such as the presence of 
HAI or not which is possible from 
routine data and may not require 
data collection. 
 
Leads to biased estimates 
because patients in the infected 
group tend to be sicker and 
ignores time-exposure. Suffers 
from selection and time-
dependent bias.  
[47, 53, 66, 
73, 89, 90, 
97-99, 105, 
109, 110, 
118, 119] 
Matching (Simple)  Matching methods are very 
popular and include one to one or 
to more than one matching and 
matching using propensity scores. 
Usually matching methods 
compare mean LOS between the 
two matched groups and “simple” 
here denotes matching on any 
characteristic other than the time 
a patient has stayed in hospital up 
to the point of infection (time to 
infection).  
Easy to use and there are many 
techniques available to match 
cases to controls. Usual matching 
factors include: Age, sex, 
comorbidities and ward or 
admission type. It is possible to 
use other statistical techniques on 
a matched sample. 
Simple matching when estimating 
the extra LOS due to infection 
gives biased estimates due to 
time-dependent bias. This bias 
occurs because the time before 
infection is used when estimating 
the extra LOS. There is also a 
trade-off between accuracy and 
maximising successful matches. 
[32, 35, 41-
43, 45, 49, 
54, 57, 58, 
61, 64, 74, 
75, 77, 79, 
81, 83, 85, 
87, 88, 92-
95, 103, 104, 
111, 113, 
116, 117] 
Regression  
 
These methods estimate LOS 
attributable to HAI by controlling 
for a range of patient 
characteristics and comorbidities 
using linear regression    
Fairly straightforward methods 
that can be used to estimate the 
impact of HAI on LOS. Ease of 
estimation and interpretation. 
Ease of controlling for 
comorbidities. 
Regression methods do not 
control for the timing of events so 
they suffer from time-dependent 
bias. 
[34, 36, 44, 
46, 48, 55, 
56, 62, 71, 
72, 76, 78, 
82, 84, 91, 
96, 100-102, 
106, 107, 
112, 114, 
115] 
Matching (Time) Methods that primarily match on 
the time to infection for 
controlling time-dependent HAI 
exposure. Controls are required to 
have spent as much time in 
hospital as the case at the time of 
infection. Other matching factors 
include age, sex, comorbidities.   
In addition to usual factors 
matching can include exposure 
time. Matching using incidence 
density sampling, which also 
matches on time to infection, has 
been suggested as the best way to 
mitigate time-dependent bias.  
 
Simply adding time to infection as 
a matching factor will not 
completely eliminate time-
dependent bias. Incidence density 
matching performs better but it is 
a complicated procedure which is 
second best to truly time-varying 
methods such as multistate 
modelling.  
[22, 31, 37-
40, 51, 52, 
60, 65, 68, 
70] 
Survival Analysis Cox survival models treating HAI 
as time-fixed covariate but can be 
adapted to control for time-
dependent bias.   
Survival methods can be adapted 
for time-dependent analysis using 
Cox models producing unbiased 
estimates. Can adjust for 
comorbidities.  
Survival methods require more in 
depth statistical knowledge and 
data manipulation to control for 
time dependence. Proportional 
hazards models use strong 
assumptions that are not always 
realistic.  
[59, 86] 
Multistate Modelling Patient data are modelled 
between a set of states over time 
such as HAI and discharge. A 
survival analysis is then run for 
every transition (a change from 
one state to the other such as 
hospital to HAI or discharged). 
This method treats HAI as a time-
dependent exposure therefore 
properly controlling for the 
occurrence of events over the 
course of time. Competing-risks 
can be analysed at the same time. 
Basic multistate analysis can be 
performed with a pocket 
calculator. 
Multistate modelling can be 
complicated and requires data 
preparation and specialised 
software to be able to control for 
other important covariates such 
as comorbidities. Even then 
controlling for characteristics can 
only be done indirectly.   
[4, 27, 33, 50, 
63, 67, 69, 
80, 108] 
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